Conflict of interest PW reports grant income from Roche Diagnostics, AstraZeneca, Boehringer Ingelheim, and Novartis, and speaker fees from Novo Nordisk and Raisio Nutrition. JBB reports salary support from clinical trial contracts to his employer by Corcept, Dexcom, GentiBio, and Novo Nordisk; personal compensation for consulting from Aardvark Therapeutics, Altimmune, Alveus Therapeutics, Amgen, Antag, Aqua Medical, AstraZeneca, Boehringer-Ingelheim, Corcept Therapeutics, Dexcom, Eli Lilly, embecta, General Medicines Inc, GentiBio, Insulet, Kayothera, Metsera, MiniMed, Novo Nordisk, Recordati, Sparrow Pharmaceuticals, Tandem, Vertex, vTv Therapeutics, and Zealand; stock/options in Glyscend, Mellitus Health, Metsera, Pendulum Therapeutics, Praetego, and Stability Health. HS is on the advisory board and speaker’s bureau of Boehringer Ingelheim, Novo Nordisk, Sanofi-Aventis, Amgen, AstraZeneca, Bayer, Eli Lilly, Kapsch, MSD, and Daiichi Sankyo. AFH reports research support and/or honoraria from AstraZeneca, Boehringer Ingleheim, Boston Scientific Corporation, Bristol Myers Squibb, Eidos Therapeutics, Intellia, Intercept, Merck, Novartis, Novo Nordisk, Prolaio, TikkunLev Therapeutics, Inc. RRH reports personal fees from Lilly, Merck KGaA, MitoRx, Novartis and Owen Mumford Ltd. SHS reports researching funding from AstraZeneca. RJM reports research support and/or honoraria from Abbott, Alleviant Medical, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, Cytokinetics, Daiichi Sankyo, Edwards, Eli Lilly, Endotronix, Lexicon, Medtronic, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Pharmacosmos, Reprieve Cardiovascular, Respicardia, Roche, Rocket Pharmaceuticals, Vifor, Windtree Therapeutics, and Zoll. All other authors report no relevant disclosures.
PubMed
